This unique program offers outstanding clinical training and research opportunities in infectious diseases, vaccine development, and public health.
The fellowship is supported through a T32 training grant from the National Institutes of Health in vaccinology. The clinical training takes place at the University of Maryland Children's Hospital, a large tertiary level referral hospital with all pediatric and surgical sub-specialty services. Faculty members are committed to education and professional development of the fellows.
We offer outstanding opportunities for research in vaccine development and international health. The CVD is an international leader in the development and evaluation of vaccines, with a focus on diseases that have the greatest burden among children in developing countries. Research ranges from basic pathogenesis, vaccine development and immunology, to epidemiology, clinical trials and public health research in domestic and international settings. This position is open to individuals who have successfully completed a pediatric residency program. Fellows who have completed one year of clinical training elsewhere and still need to fulfill their research requirements may also apply. US citizenship or Green Card is required.
Please contact PedsID@som.umaryland.edu for additional information and visit the Division of Infectious Disease & Tropical Pediatrics website.
Dr. Berry studies the humoral immune response to malaria following natural infection and malaria vaccination. She co-leads the Immunoepidemiology and Pathogenesis Unit within the Malaria Research Program with Dr. Travassos. She uses protein and peptide microarrays to simultaneously profile the antibody reactivity to hundreds to thousands of malaria proteins and peptides. Her goal is to identify signatures of antibody responses that are associated with protection from malaria illness to inform next generation malaria vaccine design.
Dr. Berry is a member of the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine and Treatment Evaluation Unit (VTEU) network of investigators. Recent NIAID clinical studies have included trials of pandemic and seasonal influenza vaccines, a study of concurrent use of both licensed brands of rotavirus vaccines within the same schedule, and a study of the immunogenicity of Human Papilloma Virus vaccine when given outside of the recommended schedule.
Dr. James Campbell’s research interests include clinical trials of vaccines in all age groups, epidemiology of vaccine-preventable diseases, and HIV prevention. He has performed trials of vaccines against many organisms, including Neisseria meningitidis, Bacillus anthracis, seasonal influenza, pandemic influenza, and smallpox. Dr. Campbell has overseen trials for innovative vaccine administration techniques and coordinated vaccine trials of childhood immunizations at three pediatric clinic vaccine sites in Maryland.
He helped establish and oversee a microbiology laboratory at the pediatric hospital in Bamako, Mali where they investigated the causes of invasive bacterial infections, particularly Streptococcus pneumoniae and Haemophilus influenzae type b. From 2007 to 2012, he was a medical officer/epidemiologist with CDC’s Division of HIV/AIDS Prevention and the in-country Associate Director for Science in Kampala, Uganda. Dr. Campbell's work in Uganda included HIV prevention trials and research on Nodding Syndrome and other outbreaks.
Karen Kotloff, MD is a world-renowned pediatrician-scientist in vaccine development and the epidemiology of infectious diseases at the University of Maryland School of Medicine. Her footprint reaches far beyond an extensive list of publications, grants, and awards. Dr. Kotloff has characterized infections burdening the world’s most vulnerable children and participated in the clinical development of, and advocacy for, use of vaccines against a wide range of infections, including group A streptococcus, Shigella, and influenza.
Dr. Kotloff led the clinical and epidemiologic components of the largest global epidemiology study on the causes of childhood diarrhea, the Global Enterics Multicenter Study (GEMS). The work revolutionized our understanding of diarrheal diseases in some of the most disadvantaged areas of the world. GEMS highlighted the major causes of infectious diarrhea and led to the re-prioritization of development and implementation efforts to combat the leading pathogens. As a follow-on to GEMS, Dr. Kotloff is leading the Vaccine Impact on Diarrhea in Africa (VIDA) study to assess the causes and burden of diarrhea in children under five and determine the effectiveness of rotavirus vaccine in Mali, Kenya, and The Gambia.
She is Principal Investigator (PI) of the Vaccine Treatment and Evaluation Unit (VTEU) at the CVD, a critical entity in developing new and improved vaccines and therapeutics against infectious diseases of public health importance. The VTEU is funded by the National Institute of Allergy and Infectious Diseases.
Dr. Kotloff mentors faculty, administrators, students, and investigators, both domestically and internationally and is a tireless promoter of solid, evidence-based science, ethical research, compassionate care, and pediatric public health needs. She participates in numerous international advisory committees for the Bill & Melinda Gates Foundation and the World Health Organization and.serves on the Vaccines and Related Biological Products Advisory Committee providing recommendations to the Food and Drug Administration on safety, effectiveness, and use of vaccines.
In 2001, Dr. Kotloff was instrumental in the creation of the Center for Vaccine Development, Mali (CVD-Mali), now a premier research and public health institution in West Africa. Her work contributed to the determination of Haemophilus influenzae type b (Hib) disease burden, introduction of the Hib vaccine, and the reduction of disease incidence.
Dr. Laufer is a pediatric infectious disease specialist, with a primary research interest in malaria and global child health. She has conducted research, clinical care and professional education in several resource-limited countries, but has dedicated the past 15 years to working in Malawi. She and her research team use clinical and laboratory research to develop and evaluate interventions to decrease the burden of malaria in sub-Saharan Africa. Dr. Laufer received an NIH Fogarty International Center grant in 2016, which supports training in molecular epidemiology, biostatistics and vector biology to promote efforts to eliminate malaria and the other infectious diseases that threaten the health of children in the region. She currently serves as Principal Investigator for clinical trials and epidemiological studies throughout Malawi.
Her current research focuses on malaria during pregnancy and its impact on infants, the interaction between HIV and malaria and identifying reservoirs of malaria transmission. Her laboratory at the University of Maryland explores the application of molecular epidemiology tools to address critical issues related to malaria pathogenesis, disease burden and drug resistance.
Dr. Laufer serves as the Associate Director for the Center for Vaccine Development and Global Health (CVD). She leads outreach efforts throughout the School of Medicine and the entire University of Maryland campus to support and promote global health research.
Dr. Laurens is a pediatric infectious disease specialist with a primary research interest in malaria and antimalarial immunity. He conducts studies at the Center for Vaccine Development (CVD) in Baltimore and at international sites in Burkina Faso, Mali, and Malawi. Dr. Laurens evaluates malaria vaccines and therapeutics, to study the interaction of HIV and malaria and to investigate the acquisition of antimalarial immunity. The broad goal of Dr. Laurens’ research is to illuminate the mechanisms of immunity to malaria with the aim to inform development of malaria vaccines and therapeutics.
He has served as a consultant to the WHO Initiative for Vaccine Research to develop guidelines for the design and conduct of malaria challenge trials, including guidelines for microscopy diagnostics and clinical management. Dr. Laurens has significant experience in vaccine trials in limited resource settings, including first-in-human studies conducted under IND with safety endpoints; he played a critical role in the clinical development plan of Sanaria’s PfSPZ Vaccine from the very first-in-human clinical trial at University of Maryland Baltimore to a current dose escalation study in malaria-exposed adults in Burkina Faso.
Dr. Laurens is also involved in a pediatric typhoid conjugate vaccine trial in Malawi, which is the first of its kind on the African continent. He also helps to lead a complementary study of pediatric typhoid conjugate vaccine in infants and children in Burkina Faso.
Dr. Laurens directs the Pediatric Infectious Diseases Fellowship Program at the University of Maryland School of Medicine, where the most promising pediatric infectious disease physician-scientists are trained in clinical care and research.
Dr. McArthur’s research interests span the spectrum of vaccine development to include pre-clinical studies, translational immunology, and clinical trials. Her overarching research goal is to advance vaccine development to prevent infection in resource-limited countries. For almost a decade, Dr. McArthur has focused on interactions between pathogens and the host immune response – identifying immunological correlates of protection following vaccination.
Dr. McArthur works with a number of pathogens of global public health importance, including enteric bacteria such as Salmonella Typhi, Enterotoxigenic Escherichia coli (ETEC), and Vibrio cholerae, as well as arboviruses, such as Zika, dengue, and yellow fever viruses. While many diseases caused by these pathogens are rare in the United States, they continue to cause significant morbidity, mortality, and economic hardship in low and middle-income countries.
As the Principal Investigator (PI) for a Robert Wood Johnson Foundation, Harold Amos Medical Faculty Development Program Career Development Award, Dr. McArthur investigates the role of T cells in protection against cholera. She is using data from a vaccination and wild-type challenge clinical trial conducted at the CVD to perform in-depth immunophenotyping of V. cholerae-responsive T cell subsets (e.g., effector memory CD4+ T cells, circulating T follicular helper cells – cTfh) using mass cytometry. She also explores the mechanisms by which T cells provide B cell “help” in hopes of identifying correlates of vaccine-induced protection.
Dr. McArthur also researches immunological responses induced by flaviviruses, including Zika and dengue, and vaccine development against these viruses. Zika virus is a mosquito-borne flavivirus that inflicts devastating neurological defects on infants born to mothers infected during pregnancy. This emerging virus has spread geographically and may continue to affect naïve populations. To halt further cases an effective vaccine is urgently needed. Dr. McArthur is the site PI for a National Institutes of Health (NIH) Phase I/Ib clinical trial to evaluate the safety and immunogenicity of a candidate Zika virus DNA vaccine, a collaborative project with the NIH Vaccine Research center and Emory University.
Dr. Tapia’s research focuses primarily on the epidemiology of vaccine-preventable diseases in Mali and the development of vaccines to address these diseases. In conjunction with the team at CVD-Mali (Centre pour le Développement des Vaccins - Mali), headed by Dr. Samba Sow, she has conducted and participated in the following vaccine-development activities:
In addition to assisting in the development of these important vaccines, Dr. Tapia and the CVD-Mali team have described the epidemiology of pediatric infections with Haemophilus influenzae type b and Streptococcus pneumoniae. These data have led to the introduction of life-saving vaccines (Hib conjugate vaccine and 13-valent pneumococcal conjugate vaccine) into the Malian Expanded Programme on Immunization.
Dr. Travassos is a pediatric infectious diseases specialist and member of the Center for Vaccine Development and Global Health’s Malaria Research Group. He co-leads the Immunoepidemiology and Pathogenesis Unit within the Malaria Research Program with Dr. Berry. His research focuses on malaria pathogenesis and epidemiology, with a focus on cerebral malaria and other forms of severe malaria. Dr. Travassos is particularly interested in malaria parasite variant surface antigens and their contribution to the development of cerebral malaria. He employs novel immune techniques such as microarray analysis to probe the human response to P. falciparum malaria.
Dr. Travassos currently studies cerebral malaria in Mali, and this project focuses on novel genomic and proteomic approaches with the use of a new animal model to measure the association between particular variant surface antigens and the development of cerebral malaria and also protective natural immunity. His research also includes work in Ethiopia assessing vaccine coverage through the use of serosurveys.
Certificate in clinical research (12 credits)
Master of Science in Clinical Research (MSCR, 30 credits)